Before you sell to, join or invest in Immunomic Therapeutics, Inc.
MentionFox check on Immunomic Therapeutics, Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/immunomic-therapeutics-inc-form-d-25000001
Check Immunomic Therapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Immunomic Therapeutics, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
Immunomic Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-06-02.
Immunomic Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 2, 2025. The filing reports $6.50M sold. Its industry group is Biotechnology. It names Dong-Gun Kim (Executive Officer, Director), Robert Ahlgren (Director), Steve Park (Director) (SEC Form D, June 2, 2025).
Is this your company?
Sell to companies like Immunomic Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-06-02 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Immunomic Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Immunomic Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in Maryland, filed within 90 days of this one, largest first.
Get an email when Immunomic Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Immunomic Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Immunomic Therapeutics, Inc. →Get the full cited report on Immunomic Therapeutics, Inc.
What the filing shows about Immunomic Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immunomic Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Immunomic Therapeutics, Inc.'s address as Attn: Erin Duffy, 15010 Broschart Rd., Suite 250, Rockville, MD 20850.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Immunomic Therapeutics, Inc. See pricing
Immunomic Therapeutics, Inc. is a registered filer with the SEC (CIK 1543256) and has filed since 2024-04-10. 2 filings are on record, the latest on 2025-06-02.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Immunomic Therapeutics, Inc.'s Form D of 2025-06-02 names Dong-Gun Kim, Robert Ahlgren, Steve Park and 4 more as its officers, directors or promoters.
Its new offerings report $9.50M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Dong-Gun Kim is named as Executive Officer and Director on the Form D that Immunomic Therapeutics, Inc. filed with the SEC on 2 June 2025, one of 7 people that filing names.
Robert Ahlgren is named as Director on the Form D that Immunomic Therapeutics, Inc. filed with the SEC on 2 June 2025, one of 7 people that filing names.
Steve Park is named as Director on the Form D that Immunomic Therapeutics, Inc. filed with the SEC on 2 June 2025, one of 7 people that filing names.
Ki-Hong Ahn is named as Director on the Form D that Immunomic Therapeutics, Inc. filed with the SEC on 2 June 2025, one of 7 people that filing names.
Matthew Chang is named as Director on the Form D that Immunomic Therapeutics, Inc. filed with the SEC on 2 June 2025, one of 7 people that filing names.
James Wishart is named as Director on the Form D that Immunomic Therapeutics, Inc. filed with the SEC on 2 June 2025, one of 7 people that filing names.
Yang Gon Jin is named as Director on the Form D that Immunomic Therapeutics, Inc. filed with the SEC on 2 June 2025, one of 7 people that filing names.
7 people named on the filing — 1 holding an executive role and 6 as directors only.
Named as of the 2025-06-02 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Immunomic Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Immunomic Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Immunomic Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Immunomic Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Immunomic Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Immunomic Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Washington, DC
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/immunomic-therapeutics-inc-form-d-25000001